1. Home
  2. IRWD vs FATE Comparison

IRWD vs FATE Comparison

Compare IRWD & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRWD
  • FATE
  • Stock Information
  • Founded
  • IRWD 1998
  • FATE 2007
  • Country
  • IRWD United States
  • FATE United States
  • Employees
  • IRWD N/A
  • FATE N/A
  • Industry
  • IRWD Biotechnology: Pharmaceutical Preparations
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • IRWD Health Care
  • FATE Health Care
  • Exchange
  • IRWD Nasdaq
  • FATE Nasdaq
  • Market Cap
  • IRWD 111.2M
  • FATE 125.7M
  • IPO Year
  • IRWD 2010
  • FATE 2013
  • Fundamental
  • Price
  • IRWD $1.03
  • FATE $1.09
  • Analyst Decision
  • IRWD Buy
  • FATE Hold
  • Analyst Count
  • IRWD 5
  • FATE 7
  • Target Price
  • IRWD $4.94
  • FATE $3.58
  • AVG Volume (30 Days)
  • IRWD 1.5M
  • FATE 1.6M
  • Earning Date
  • IRWD 08-07-2025
  • FATE 08-12-2025
  • Dividend Yield
  • IRWD N/A
  • FATE N/A
  • EPS Growth
  • IRWD N/A
  • FATE N/A
  • EPS
  • IRWD N/A
  • FATE N/A
  • Revenue
  • IRWD $308,519,000.00
  • FATE $8,470,000.00
  • Revenue This Year
  • IRWD N/A
  • FATE N/A
  • Revenue Next Year
  • IRWD N/A
  • FATE N/A
  • P/E Ratio
  • IRWD N/A
  • FATE N/A
  • Revenue Growth
  • IRWD N/A
  • FATE N/A
  • 52 Week Low
  • IRWD $0.53
  • FATE $0.66
  • 52 Week High
  • IRWD $5.21
  • FATE $4.20
  • Technical
  • Relative Strength Index (RSI)
  • IRWD 63.45
  • FATE 49.33
  • Support Level
  • IRWD $0.81
  • FATE $0.91
  • Resistance Level
  • IRWD $1.16
  • FATE $1.24
  • Average True Range (ATR)
  • IRWD 0.11
  • FATE 0.09
  • MACD
  • IRWD 0.02
  • FATE 0.00
  • Stochastic Oscillator
  • IRWD 70.45
  • FATE 42.86

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: